Search
"ChemPartner" Secures Nearly RMB 170 Million in Pre-A Funding Round
2025-07-18 /
Read about 0 minute
Author：小编
ChemPartner (Chengdu) Co., Ltd. has recently announced the successful completion of a Pre-A funding round, raising approximately RMB 170 million. This round was spearheaded by SDIC Ventures, with additional participation from China Venture Capital Fund, Guosheng Innovation, and existing investor Longpan Investment. The capital raised will be strategically allocated to expedite the global early clinical development of two core products: SN3001, a therapeutic vaccine for prostate cancer, and SN2001, an immunotherapeutic vaccine for chronic hepatitis B. Additionally, the funds will support the enhancement of the R&D center and the strategic deployment of subsequent tumor therapeutic vaccine products.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
